RxDoctor Payments Data

Brittney Ramirez, APRN

Family · Nashville, TNNPI 1831893536

Payments from drug & device makers

$1,892in general payments, 2019–2025

Across 102 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$438
  • Sanofi$393
  • GSK$333
  • Regeneron Healthcare Solutions, Inc.$199
  • Boehringer Ingelheim$150
  • Grifols USA, LLC$108
  • plus $272 from 7 others

What the payments were for

  • Food & beverage$1,892100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,892 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$27,234
Medicare patients
210
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter184$156,214
Breztri AerosphereBudesonide/Glycopyr/Formoterol118$84,414
Dupixent PenDupilumab16$72,520
Breo ElliptaFluticasone/Vilanterol44$20,880
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,906
SymbicortBudesonide/Formoterol Fumarate40$9,853
Advair HfaFluticasone Propion/Salmeterol23$8,655
Albuterol Sulfate HfaAlbuterol Sulfate311$7,394
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$3,865
BreynaBudesonide/Formoterol Fumarate17$2,511
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$2,453
Ventolin HfaAlbuterol Sulfate20$1,270
Montelukast Sodium132$1,104
Levalbuterol Tartrate HfaLevalbuterol Tartrate21$1,053
Roflumilast19$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$333$188,000242 claims
AstraZenecaBreztri Aerosphere, Symbicort$438$94,267158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →